<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397213</url>
  </required_header>
  <id_info>
    <org_study_id>2014-004610-29</org_study_id>
    <nct_id>NCT02397213</nct_id>
  </id_info>
  <brief_title>Ciclosporin to Protect Renal Function In Cardiac Surgery</brief_title>
  <acronym>CiPRICS</acronym>
  <official_title>Ciclosporin to Protect Renal Function In Cardiac Surgery: CiPRICS A Phase II Double Blind Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroVive Pharmaceutical AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential of ciclosporin in reducing risk and
      degree of acute kidney injury after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) is a common complication after cardiac surgery and is associated
      with decreased long-term survival. The mechanism for inducing acute kidney injury is unknown
      but ischaemia-reperfusion injury is indicated to be a part of the cause.

      Animal studies have showed cytoprotective, preconditioning and anti-apoptotic effects of
      ciclosporin in ischaemia-reperfusion injury in the kidney. The major mechanism is thought to
      be inhibition of the reperfusion triggered opening of the mitochondrial permeability
      transition pore (mPTP), responsible for reperfusion-induced necrosis. During cardiac surgery,
      the period of extracorporeal circulation (ECC) changes the perfusion through the kidney.
      Return to normal perfusion with a beating heart has similarities with reperfusion following
      ischemia.

      Administration of ciclosporin in conjunction with percutaneous coronary intervention (PCI),
      heart surgery and traumatic brain injury (TBI) in humans has shown to be safe with no direct
      side-effects.

      The investigators therefore hypothesize that a preconditioning effect of ciclosporin before
      coronary artery bypass grafting (CABG) can reduce the level of renal dysfunction after this
      type of cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ciclosporin to Protect Renal function In Cardiac Surgery.</measure>
    <time_frame>up to day 3</time_frame>
    <description>Relative P-CyC change from day -1 to day 3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <description>Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.</description>
    <arm_group_label>Ciclosporin</arm_group_label>
    <other_name>CicloMulsion® ATC-code: CO1EB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-emergent CABG

          -  Written informed consent to participate

          -  Preoperative CyC eGFR or MDRD eGFR is 90-15.

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Hypersensitivity to ciclosporin or any of the excipients of the lipid emulsion,
             including egg-, soya- or peanut protein

          -  Pregnancy or fertile woman

          -  Ciclosporin treatment within 4 weeks

          -  Ongoing malignancy, ongoing immunosuppressive treatment, severe hepatic dysfunction,
             dialysis or severe infection

          -  Ongoing medication with dabigatran, aliskiren, bosentan, stiripentol, glibenclamid, St
             John's worth, or

          -  Off-pump surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Bjursten, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciclosporin</keyword>
  <keyword>Acute Kidney injury</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Safety</keyword>
  <keyword>Cystatin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

